Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 15


Altered phosphorylation, electrophysiology, and behavior on attenuation of PDE4B action in hippocampus.

Campbell SL, van Groen T, Kadish I, Smoot LHM, Bolger GB.

BMC Neurosci. 2017 Dec 2;18(1):77. doi: 10.1186/s12868-017-0396-6.


Multiple Behavior Phenotypes of the Fragile-X Syndrome Mouse Model Respond to Chronic Inhibition of Phosphodiesterase-4D (PDE4D).

Gurney ME, Cogram P, Deacon RM, Rex C, Tranfaglia M.

Sci Rep. 2017 Nov 7;7(1):14653. doi: 10.1038/s41598-017-15028-x.


cAMP signaling in brain is decreased in unmedicated depressed patients and increased by treatment with a selective serotonin reuptake inhibitor.

Fujita M, Richards EM, Niciu MJ, Ionescu DF, Zoghbi SS, Hong J, Telu S, Hines CS, Pike VW, Zarate CA, Innis RB.

Mol Psychiatry. 2017 May;22(5):754-759. doi: 10.1038/mp.2016.171. Epub 2016 Oct 11.


Psychiatric aspects of phosphodiesterases: An overview.

Murthy VS, Mangot AG.

Indian J Pharmacol. 2015 Nov-Dec;47(6):594-9. doi: 10.4103/0253-7613.169593. Review.


RACK1 and β-arrestin2 attenuate dimerization of PDE4 cAMP phosphodiesterase PDE4D5.

Bolger GB.

Cell Signal. 2016 Jul;28(7):706-12. doi: 10.1016/j.cellsig.2015.08.003. Epub 2015 Aug 6.


A new model of Pde4d deficiency: genetic knock-down of PDE4D enzyme in rats produces an antidepressant phenotype without spatial cognitive effects.

Schaefer TL, Braun AA, Amos-Kroohs RM, Williams MT, Ostertag E, Vorhees CV.

Genes Brain Behav. 2012 Jul;11(5):614-22. doi: 10.1111/j.1601-183X.2012.00796.x. Epub 2012 May 8.


Chronic fluoxetine treatment increases daytime melatonin synthesis in the rodent.

Reierson GW, Mastronardi CA, Licinio J, Wong ML.

Clin Pharmacol. 2009;1:1-6. doi: 10.2147/CPAA.S7157. Epub 2009 Sep 7.


Phosphodiesterase function and endocrine cells: links to human disease and roles in tumor development and treatment.

Levy I, Horvath A, Azevedo M, de Alexandre RB, Stratakis CA.

Curr Opin Pharmacol. 2011 Dec;11(6):689-97. doi: 10.1016/j.coph.2011.10.003. Epub 2011 Oct 31. Review.


Antidepressant potential of nitrogen-containing heterocyclic moieties: An updated review.

Siddiqui N, Andalip, Bawa S, Ali R, Afzal O, Akhtar MJ, Azad B, Kumar R.

J Pharm Bioallied Sci. 2011 Apr;3(2):194-212. doi: 10.4103/0975-7406.80765.


Control of melanocyte differentiation by a MITF-PDE4D3 homeostatic circuit.

Khaled M, Levy C, Fisher DE.

Genes Dev. 2010 Oct 15;24(20):2276-81. doi: 10.1101/gad.1937710.


Pivotal effects of phosphodiesterase inhibitors on myocyte contractility and viability in normal and ischemic hearts.

Rao YJ, Xi L.

Acta Pharmacol Sin. 2009 Jan;30(1):1-24. doi: 10.1038/aps.2008.1. Epub 2008 Dec 8. Review.


Developmental etiology for neuroanatomical and cognitive deficits in mice overexpressing Galphas, a G-protein subunit genetically linked to schizophrenia.

Kelly MP, Stein JM, Vecsey CG, Favilla C, Yang X, Bizily SF, Esposito MF, Wand G, Kanes SJ, Abel T.

Mol Psychiatry. 2009 Apr;14(4):398-415, 347. doi: 10.1038/mp.2008.124. Epub 2008 Nov 25. Erratum in: Mol Psychiatry. 2009 Dec;14(12):1145.


The PDE4 inhibitor rolipram reverses object memory impairment induced by acute tryptophan depletion in the rat.

Rutten K, Lieben C, Smits L, Blokland A.

Psychopharmacology (Berl). 2007 Jun;192(2):275-82. Epub 2007 Jan 30.


Rolipram: a specific phosphodiesterase 4 inhibitor with potential antipsychotic activity.

Kanes SJ, Tokarczyk J, Siegel SJ, Bilker W, Abel T, Kelly MP.

Neuroscience. 2007 Jan 5;144(1):239-46. Epub 2006 Nov 1.


Phosphodiesterase inhibitors: new opportunities for the treatment of asthma.

Torphy TJ, Undem BJ.

Thorax. 1991 Jul;46(7):512-23. Review. No abstract available.

Supplemental Content

Support Center